Correction: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial.
[This corrects the article DOI: 10.1371/journal.pone.0263252.].
Main Authors: | Elliot Marseille, Jennifer M Mitchell, James G Kahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0269623 |
Similar Items
-
Correction: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
by: Elliot Marseille, et al.
Published: (2022-01-01) -
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial.
by: Elliot Marseille, et al.
Published: (2022-01-01) -
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
by: Elliot Marseille, et al.
Published: (2020-01-01) -
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder
by: Richard J. Zeifman, et al.
Published: (2024-01-01) -
MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial
by: Candice M. Monson, et al.
Published: (2020-12-01)